Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization

Chang, Jen Jen; Charalel, Resmi A.; Noda, Christopher; Ramaswamy, R.; Kim, Seung Kwon; Darcy, Michael; Foltz, Gretchen; Akinwande, Olaguoke

doi:10.21873/anticanres.12563

Cited by 14 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirdly, TACE and TARE were deemed as one kind of therapy in this study to establish a network, since no significant difference was reported between TACE and TARE. [23,45] Consequently, findings of the current network meta-analysis might not completely conform to the clinical practice to some extent.…”

Section: Discussionmentioning

confidence: 94%

Efficacy of treatment regimens for advanced hepatocellular carcinoma

Chen

Huang

et al. 2019

Medicine

View full text Add to dashboard Cite

Background:This study aimed to perform a network meta-analysis to evaluate the therapeutic effect and safety of various modalities in treating advanced hepatocellular carcinoma (HCC). Typically, the modalities of interest were comprised of sorafenib, transarterial chemoembolization (TACE), sorafenib combined with TACE, TACE combined with traditional Chinese medicine (TCM), and sorafenib combined with hepatic arterial infusion chemotherapy (HAIC).Methods:Potentially eligible studies were systemically retrieved from the electronic databases (including PubMed and Cochrane Library) up to September 2018. The overall survival (OS) associated with the 5 modalities of interest enrolled in this study was compared by means of network meta-analysis. Meanwhile, major adverse events (AEs) were also evaluated.Results:The current network meta-analysis enrolled 7 published randomized controlled trials (RCTs), and the pooled results indicated that the TACE-TCM regimen displayed the highest efficacy in treating advanced HCC, followed by HAIC-sorafenib. By contrast, the TACE alone and sorafenib alone regimens had the least efficacy. Relative to other regimens of interest, the TACE-TCM regimen was associated with less incidence of treatment-associated AEs.Conclusion:The TACE-TCM regimen was associated with higher treatment responses in advanced HCC patients than those of the other regimens of interest.

show abstract

Section: Discussionmentioning

confidence: 94%

Efficacy of treatment regimens for advanced hepatocellular carcinoma

Chen

Huang

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…There were an astonishing 26 complete responders (7.2%); 132 partial responders (38.1%); 133 patients (36.7%) with stable disease; and 58 patients (16%) had disease progression. mOS data from six studies (11,(48)(49)(50)(51)(52) showed a median of 19.6 months (4.6-32 months). One-year survival data was provided in four studies (12,47,49,51) ranging from 32 to 88.8%.…”

Section: Transarterial Chemoembolization (Tace) and Transarterial Radmentioning

confidence: 99%

“…Y-90 is the most commonly used radioembolizing product. A total of nine studies provided RECIST response data (11,(38)(39)(40)(42)(43)(44)(45)(46). There were nine complete responders (2.3%) out of the 380 total patients.…”

Section: Transarterial Chemoembolization (Tace) and Transarterial Radmentioning

confidence: 99%

“…One hundred forty-three patients (37.6%) had partial response; 139 patients (36.5%) had stable disease; and 44 patients (11.5%) had disease progression. Eight studies provided a mOS (11,(40)(41)(42)(43)(44)(45)(46). The mOS of the pooled data was 11.5 months (6.6-13.6 months).…”

Section: Transarterial Chemoembolization (Tace) and Transarterial Radmentioning

confidence: 99%

“…Three studies provided 1-year survival data (39,44,45) which ranged from 34.5 to 86%. COX regression analysis was reported in four studies (11,42,45,46). Through univariate analysis, SUVmax response, lower volume of hepatic parenchyma involvement, chemotherapy after TARE, and radiologic response to treatment were identified as factors improving overall survival.…”

Section: Transarterial Chemoembolization (Tace) and Transarterial Radmentioning

confidence: 99%

See 2 more Smart Citations

Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review

2021

View full text Add to dashboard Cite

BackgroundThe liver is the second most common site of breast cancer metastasis. Liver directed therapies including hepatic resection, radiofrequency ablation (RFA), transarterial chemo- and radioembolization (TACE/TARE), and hepatic arterial infusion (HAI) have been scarcely researched for breast cancer liver metastasis (BCLM). The purpose of this review is to present the known body of literature on these therapies for BCLM.MethodsA systematic review was performed with pre-specified search terms using PubMed, MEDLINE, EMBASE, and Cochrane Review resulting in 9,957 results. After review of abstracts and application of exclusion criteria, 51 studies were included in this review.ResultsHepatic resection afforded the longest median overall survival (mOS) and 5-year survival (45 mo, 41%) across 23 studies. RFA was presented in six studies with pooled mOS and 5-year survival of 38 mo and 11–33%. Disease burden and tumor size was lower amongst hepatic resection and RFA patients. TACE was presented in eight studies with pooled mOS and 1-year survival of 19.6 mo and 32–88.8%. TARE was presented in 10 studies with pooled mOS and 1-year survival of 11.5 mo and 34.5–86%. TACE and TARE populations were selected for chemo-resistant, unresectable disease. Hepatic arterial infusion was presented in five studies with pooled mOS of 11.3 months.ConclusionAlthough further studies are necessary to delineate appropriate usage of liver directed therapies in BCLM, small studies suggest hepatic resection and RFA, in well selected patients, can result in prolonged survival. Longitudinal studies with larger cohorts are warranted to further investigate the effectiveness of each modality.

show abstract